1-3 of 3
Peppy Rebello
Close
Sort by
Journal Articles

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Clinical Trials & Observations
Geoff Hale, Peppy Rebello, Lee R. Brettman, Chris Fegan, Ben Kennedy, Eva Kimby, Mike Leach, Jeanette Lundin, Håkan Mellstedt, Paul Moreton, Andy C. Rawstron, Herman Waldmann, Anders Osterborg, Peter Hillmen
Journal: Blood
Blood (2004) 104 (4): 948–955.
https://doi.org/10.1182/blood-2004-02-0593
Published: 2004
Journal Articles

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications

Brief Report
Emma C. Morris, Peppy Rebello, Kirsty J. Thomson, Karl S. Peggs, Charalampia Kyriakou, Anthony H. Goldstone, Stephen Mackinnon, Geoff Hale
Journal: Blood
Blood (2003) 102 (1): 404–406.
https://doi.org/10.1182/blood-2002-09-2687
Published: 2003
Journal Articles

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Clinical Trials & Observations
Jeanette Lundin, Eva Kimby, Magnus Björkholm, Per-Anders Broliden, Fredrik Celsing, Viktoria Hjalmar, Lars Möllgård, Peppy Rebello, Geoff Hale, Herman Waldmann, Håkan Mellstedt, Anders Österborg
Journal: Blood
Blood (2002) 100 (3): 768–773.
https://doi.org/10.1182/blood-2002-01-0159
Published: 2002